Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28534465 | 0.87 | TDP1 (0.58) | ACHELMNAKMT2AL3MBTL1TDP1 | |
| SCHEMBL5582943 | 0.85 | ACHE (0.58) | ACHELMNAKMT2ATDP1KDM4E | |
| SCHEMBL3826570 | 0.84 | L3MBTL1 (0.56) | ACHEKMT2AL3MBTL1TDP1NPC1 | |
| SCHEMBL12337793 | 0.84 | L3MBTL1 (0.56) | ACHEKMT2AL3MBTL1TDP1NPC1 | |
| SCHEMBL10534545 | 0.83 | L3MBTL1 (0.51) | ACHELMNAKMT2AL3MBTL1TDP1 | |
| SCHEMBL2541390 | 0.83 | KDM4E (0.58) | ACHELMNAKMT2ATDP1NPC1 | |
| SCHEMBL1513505 | 0.83 | ACHE (0.56) | ACHELMNAKMT2ATDP1NPC1 | |
| SCHEMBL29535063 | 0.83 | KDM4E (0.58) | ACHELMNAKMT2ATDP1NPC1 | |
| SCHEMBL12121608 | 0.83 | KDM4E (0.68) | ACHELMNAKMT2ATDP1KDM4E | |
| SCHEMBL418274 | 0.83 | ACHE (0.56) | ACHELMNAKMT2ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146176-A | GPR133/ADGRD1 agonist, preparation method and application thereof | 山东大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-4100385-A1 | REARRANGEMENT OF DIMETHYLPHENYLACYLATES USING ZEOLITES | DSM IP Assets B.V. (NL) | 2022-12-14 | — | — | EP | disclosed |
| CN-115023413-A | Rearrangement of dimethylphenyl acrylate using zeolite | 帝斯曼知识产权资产管理有限公司 | 2022-09-06 | — | — | CN | disclosed |
| WO-2021156214-A1 | REARRANGEMENT OF DIMETHYLPHENYLACYLATES USING ZEOLITES | DSM IP ASSETS B.V. (NL) | 2021-08-12 | — | — | WO | disclosed |
| CN-107488148-A | A kind of hydrocinnamamide insecticides and preparation method thereof | 安徽省黄淮兽药有限公司 | 2017-12-19 | — | — | CN | disclosed |
| US-9448244-B2 | Compound, and method for measuring iron concentration by using novel compound as chelate color former | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150260734-A1 | NOVEL COMPOUND, AND METHOD FOR MEASURING IRON CONCENTRATION BY USING NOVEL COMPOUND AS CHELATE COLOR FORMER | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2015-09-17 | — | — | US | disclosed |
| US-8618139-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| CN-103338765-A | Novel phenyl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN INC | 2013-10-02 | — | — | CN | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-6667335-B2 | NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| EP-1358165-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030187268-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030166980-A1 | Process for the nitration of xylene isomers using zeolite beta catalyst | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2003-09-04 | — | — | US | disclosed |
| US-6610723-B2 | Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1323705-A1 | A process for the nitration of xylene isomers using zeolite beta catalyst | Council of Scientific and Industrial Research (IN) | 2003-07-02 | — | — | EP | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002060877-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | WO | disclosed |
| US-4013451-A | 2-(SUBSTITUTED PHENOXY)PROPIONIC ACID | PHILAGRO S.A. (FR) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | GRIN1, GRIN2B, GRIN3B | ACHE 267/4885LMNA 4216/4885KMT2A 377/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | ACHE 554/4885LMNA 4581/4885KMT2A 428/4885 |
| US-20030187268-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | ACHE 554/4885LMNA 4581/4885KMT2A 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.